ClinicalTrials.gg
CompletedNCT02738151BRIGHTUpdated Sep 14, 2018Results posted

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

A Phase 4 interventional study of Insulin glargine, 300U/mL and Insulin degludec, 100 U/mL in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 158 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-14.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
929
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
12th of 175
929 · median 253
Started
2016
with 7 others
Phase 4
103 of 176
2 open now
Registered
131st of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment of the 175 interventional ones that give a count, is one of 8 that started in 2016, is one of 103 in phase 4, and was the 131st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.

Secondary Objectives:

Change From Baseline in HbA1c to Week 12

To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on:

  • Change in Fasting plasma glucose (FPG);
  • Change in Fasting self-monitored plasma glucose (SMPG) and 4-point SMPG and 8-point SMPG profile;
  • Percentage of participants reaching HbA1c targets \<7% or ≤6.5%;
  • Percentage of participants reaching HbA1c targets \<7% or ≤6.5% without severe and/or confirmed hypoglycemia
  • Frequency of occurrence and diurnal distribution of hypoglycemia by American Diabetes Association (ADA) category of hypoglycemia.

To assess the safety in each treatment group.

To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO).

Percentage of participants requiring rescue therapy.

Read the detailed description

The maximum study duration per participant was approximately 27 weeks: an up to 2-week screening period, a 24-week randomized treatment period (including 12 weeks active titration), and a 7-day posttreatment safety follow-up period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with type 2 diabetes mellitus (T2DM) inadequately controlled with OADs therapy with/without GLP-1 receptor agonist at stable dose for at least 3 months.
  • Signed written .

Exclusion criteria

Exclusion criteria:

  • Age \<18 years.
  • \<7.5% or >10.5% (at screening visit). (BMI) \<25 kg/m\^2 or >40 kg/m\^2.
  • History of T2DM for less than 1 year before screening.
  • Less than 6 months before screening on OADs treatment and GLP-1 receptor agonist (if taken).
  • Current or previous insulin use except for a maximum of 8 consecutive days or totally 15 days (eg, acute illness, surgery) during the last year prior to screening.
  • Initiation of new glucose-lowering medications and/or weight loss drug in the last 3 months before screening visit.
  • Participant receiving only noninsulin antihyperglycemic drugs not approved for combination with insulin according to local labelling/local treatment guideline.
  • History of hypoglycemia unawareness or repeated episodes of severe hypoglycemia or metabolic acidosis, including hospitalization for diabetic ketoacidosis during the last 12 months prior to screening.
  • Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment, or injectable drugs) during the study period.
  • End stage renal disease.
  • Any acute or chronic condition that in the opinion of Investigator would affect the safety of participant, compliance, or study results.
  • Any to use of Toujeo® or Tresiba® as defined in the national product label, to Toujeo® or Tresiba® active ingredients or one of the .
  • Pregnant or breast-feeding women.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
929 participants (actual)

Study arms

  • Experimental
    Toujeo

    Toujeo® (Insulin glargine, 300 U/mL) subcutaneous (SC) injection once daily up to Week 24 on top of non-insulin antidiabetic treatment.

    Drug: Insulin glargine, 300U/mL · Drug: Non-insulin anti-diabetic treatment

  • Active comparator
    Tresiba

    Tresiba® (Insulin Degludec, 100 U/mL) SC injection once daily up to Week 24 on top of non-insulin antidiabetic treatment .

    Drug: Insulin degludec, 100 U/mL · Drug: Non-insulin anti-diabetic treatment

Interventions

  • DrugInsulin glargine, 300U/mL

    Drug page: Insulin Glargine

    Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).

    Also known as: HOE901-U300, Toujeo

  • DrugInsulin degludec, 100 U/mL

    Drug page: Insulin degludec

    Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L). Route of administration: subcutaneous

    Also known as: Tresiba

  • DrugNon-insulin anti-diabetic treatment

    Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c to Week 24

    Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Adjusted Least Square (LS) means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the 24-week on-treatment period.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in HbA1c to Week 12

    Change in HbA1c was calculated by subtracting baseline value from Week 12 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24

    Change in FPG was calculated by subtracting baseline value from Week 12 and Week 24 value. Adjusted LS means were obtained from MMRM including post baseline values during the 24-week on-treatment period.

    Time frame: Baseline, Week 12 and Week 24

  3. Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24

    Fasting SMPG was measured by the participant before breakfast and before the administration of the glucose-lowering agents once a day during the study. Adjusted LS means were obtained from MMRM including post baseline values during the 24 week on treatment period.

    Time frame: Baseline, Week 12 and Week 24

  4. Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point

    8-point SMPG profiles were measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

    Time frame: Baseline, Week 12 and Week 24

  5. Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point

    4-point SMPG profiles were measured at the following 4 points: prebreakfast, prelunch, predinner and bedtime.

    Time frame: Baseline, Week 12 and Week 24

  6. Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24

    The 8-point SMPG profile was measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Adjusted LS means were obtained from MMRM.

    Time frame: Baseline, Week 12 and Week 24

  7. Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24

    Adjusted LS means were obtained from MMRM. Variability was assessed by the mean of coefficient of variation calculated over at least 3 SMPG measured during the 7 days preceding the given visit.

    Time frame: Baseline, Week 12 and Week 24

  8. Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24

    Adjusted LS means were obtained from MMRM.

    Time frame: Baseline, Week 12 and Week 24

  9. Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24

    Only the post-baseline HbA1c measurements before rescue and during the 12 week and 24-week on-treatment period were considered in the analysis.

    Time frame: Week 12, and Week 24

  10. Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed by plasma glucose =\<3.9 mmol/L (=\<70 mg/dL).

    Time frame: Week 12, and Week 24

  11. Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period

    Percentage of participants With Sulphonylurea or Meglitinide dose reduction/ discontinuation due to Hypoglycemia during 24 Week treatment period were reported. Only participants with Sulphonylurea or meglitinides at Screening as per actual strata were taken into account in this analysis.

    Time frame: Baseline to Week 24

  12. Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period

    Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. Threshold values at Week 12: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.

    Time frame: Baseline to Week 24

  13. Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24

    Only the insulin dose measurements performed before initiation of rescue therapy and during the on-treatment period were considered in the analysis.

    Time frame: Baseline, Week 12 and Week 24

  14. Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks (24W)). Percentage of participants with at least one hypoglycemia (hypo) event at any time of the day were reported.

    Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period

  15. Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycaemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks).

    Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period

  16. Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L).

    Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period

  17. Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time).

    Time frame: Day 1-Week 12, Week 13-Week 24, and 24 Week Period

Other outcomes

  1. Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24

    The DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items that are answered on a Likert scale from 0 to 6. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment). Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.

    Time frame: Baseline, Week 12 and Week 24

07

Results

Posted Sep 14, 2018

Participant flow

The study was conducted at 158 study centers across 16 countries. A total of 1376 participants were screened between 19 May 2016 and 19 February 2017, of whom 447 were screen failures.

Participant flow — Overall Study
MilestoneToujeoTresiba
Started466463
Treated462462
Completed443432
Not completed2331
Withdrew: Randomized but not treated41
Withdrew: Adverse event45
Withdrew: Hypoglycemia01
Withdrew: Poor compliance to protocol43
Withdrew: Other than specified above1121

Outcome measures

PrimaryChange From Baseline in HbA1c to Week 24

Change in HbA1c was calculated by subtracting baseline value from Week 24 value. Adjusted Least Square (LS) means and standard errors were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data, using all post-baseline HbA1c data available during the 24-week on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c to Week 24
percentage of HbA1cToujeoTresiba
Change From Baseline in HbA1c to Week 24-1.64 ± 0.037-1.59 ± 0.037
Statistical analysis
  • Toujeo vs Tresiba · Mixed Models Analysis · p = <.0001 (Threshold for significance at 0.025 level.) · Least square (ls) mean difference: -0.05 · 95% CI -0.152 to 0.051Toujeo vs. Tresiba
  • Toujeo vs Tresiba · Mixed Models Analysis · p = 0.3302 · Ls mean difference: -0.05 · 95% CI -0.152 to 0.051
SecondaryChange From Baseline in HbA1c to Week 12

Change in HbA1c was calculated by subtracting baseline value from Week 12 value. Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c to Week 12
percentage of HbA1cToujeoTresiba
Change From Baseline in HbA1c to Week 12-1.37 ± 0.036-1.39 ± 0.036
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24

Change in FPG was calculated by subtracting baseline value from Week 12 and Week 24 value. Adjusted LS means were obtained from MMRM including post baseline values during the 24-week on-treatment period.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 and Week 24
mmol/LToujeoTresiba
Week 12-3.64 ± 0.099-3.89 ± 0.100
Week 24-3.52 ± 0.109-3.95 ± 0.110
SecondaryChange From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24

Fasting SMPG was measured by the participant before breakfast and before the administration of the glucose-lowering agents once a day during the study. Adjusted LS means were obtained from MMRM including post baseline values during the 24 week on treatment period.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Self-Monitoring Plasma Glucose (SMPG) to Week 12 and Week 24
mmol/LToujeoTresiba
Week 12-3.26 ± 0.067-3.25 ± 0.067
Week 24-3.23 ± 0.067-3.29 ± 0.068
SecondaryChange From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point

8-point SMPG profiles were measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · mmol/L
Change From Baseline in 8 Point SMPG Profile to Week 12 and Week 24 Per Time Point
mmol/LToujeoTresiba
Week 12: 03:00 at night-2.77 ± 3.16-2.28 ± 3.49
Week 12: Pre-breakfast-3.42 ± 2.79-3.00 ± 2.63
Week 12: 2 hours after breakfast-3.20 ± 4.02-3.23 ± 3.92
Week 12: Pre-lunch-2.64 ± 3.90-2.50 ± 3.65
Week 12: 2 hours after lunch-2.51 ± 4.15-1.99 ± 3.94
Week 12: Pre-dinner-2.04 ± 3.63-1.93 ± 3.74
Week 12: 2 hours after dinner-2.32 ± 4.20-1.76 ± 3.87
Week 12: Bedtime-2.44 ± 4.07-2.08 ± 3.95
Week 24: 03:00 at night-2.65 ± 3.43-2.43 ± 3.51
Week 24: Pre-breakfast-3.37 ± 2.81-3.03 ± 2.85
Week 24: 2 hours after breakfast-3.30 ± 3.68-3.50 ± 4.00
Week 24: Pre-lunch-2.81 ± 3.67-2.29 ± 3.93
Week 24: 2 hours after lunch-2.74 ± 3.73-1.93 ± 3.91
Week 24: Pre-dinner-1.87 ± 3.78-1.86 ± 4.01
Week 24: 2 hours after dinner-2.28 ± 4.19-2.07 ± 4.00
Week 24: Bedtime-2.52 ± 3.87-2.09 ± 3.96
SecondaryChange From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point

4-point SMPG profiles were measured at the following 4 points: prebreakfast, prelunch, predinner and bedtime.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · mmol/L
Change From Baseline in 4-point SMPG Profile to Week 12 and Week 24 Per Time Point
mmol/LToujeoTresiba
Week 12: Pre-breakfast-3.41 ± 2.75-2.97 ± 2.62
Week 12: Pre-lunch-2.63 ± 3.88-2.44 ± 3.65
Week 12: Pre-dinner-2.03 ± 3.64-1.92 ± 3.76
Week 12: Bedtime-2.41 ± 4.10-2.11 ± 3.96
Week 24: Pre-breakfast-3.38 ± 2.81-2.99 ± 2.81
Week 24: Pre-lunch-2.81 ± 3.67-2.26 ± 3.92
Week 24: Pre-dinner-1.88 ± 3.79-1.86 ± 4.01
Week 24: Bedtime-2.51 ± 3.87-2.10 ± 4.00
SecondaryChange From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24

The 8-point SMPG profile was measured at the following 8 points: 03:00 at night, pre-breakfast, 2 hours after breakfast, pre-lunch, 2 hours after lunch, pre-dinner, 2 hours after dinner, and bedtime. Adjusted LS means were obtained from MMRM.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · mmol/L
Change From Baseline in 24-hour Average 8-point SMPG Profile to Week 12 and Week 24
mmol/LToujeoTresiba
Week 12-2.57 ± 0.092-2.50 ± 0.093
Week 24-2.62 ± 0.094-2.53 ± 0.096
SecondaryChange From Baseline in Variability of Fasting SMPG to Week 12 and Week 24

Adjusted LS means were obtained from MMRM. Variability was assessed by the mean of coefficient of variation calculated over at least 3 SMPG measured during the 7 days preceding the given visit.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · percentage of mean variability
Change From Baseline in Variability of Fasting SMPG to Week 12 and Week 24
percentage of mean variabilityToujeoTresiba
Week 122.38 ± 0.4182.62 ± 0.416
Week 241.49 ± 0.3911.97 ± 0.390
SecondaryChange From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24

Adjusted LS means were obtained from MMRM.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · percentage of mean variability
Change From Baseline in Variability of 24-Hour 8-Point SMPG Profiles at Week 12 and Week 24
percentage of mean variabilityToujeoTresiba
Week 124.08 ± 0.5624.73 ± 0.561
Week 243.70 ± 0.5883.95 ± 0.599
SecondaryPercentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24

Only the post-baseline HbA1c measurements before rescue and during the 12 week and 24-week on-treatment period were considered in the analysis.

Time frame:
Week 12, and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Target HbA1c of < 7% and =<6.5% at Week 12 and Week 24
percentage of participantsToujeoTresiba
Participants who reached the target <7% at Week 1234.6336.15
Participants who reached target <=6.5% at Week 1211.4714.29
Participants who reached the target <7% at Week 2448.7044.59
Participants who reached target <=6.5% at Week 2421.2119.70
SecondaryPercentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed by plasma glucose =\<3.9 mmol/L (=\<70 mg/dL).

Time frame:
Week 12, and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Target HbA1c <7% and =<6.5% at Week 12 and Week 24 Without Severe and/or Confirmed Hypoglycemia (70 mg/dL) Event
percentage of participantsToujeoTresiba
Week12: Participants who reached the target <7%16.4513.64
Week12: Participants who reached target <=6.5%4.114.55
Week24: Participants who reached the target <7%13.4212.99
Week24: Participants who reached target <=6.5%5.845.19
SecondaryPercentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period

Percentage of participants With Sulphonylurea or Meglitinide dose reduction/ discontinuation due to Hypoglycemia during 24 Week treatment period were reported. Only participants with Sulphonylurea or meglitinides at Screening as per actual strata were taken into account in this analysis.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period
percentage of participantsToujeoTresiba
Percentage of Participants With Sulphonylurea or Meglitinide Dose Reduction/ Discontinuation Due to Hypoglycemia During 24 Weeks Treatment Period4.984.76
SecondaryPercentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period

Routine fasting SMPG and central laboratory FPG (and HbA1c after Week 12) values were used to determine the requirement of rescue medication. Threshold values at Week 12: FPG \>200 mg/dL (11 mmol/L), or HbA1c \>8.5%.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period
percentage of participantsToujeoTresiba
Percentage of Participants Requiring a Rescue Therapy During 24 Weeks Treatment Period1.301.30
SecondaryChange From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24

Only the insulin dose measurements performed before initiation of rescue therapy and during the on-treatment period were considered in the analysis.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · Units per kilogram (U/kg)
Change From Baseline in Basal Insulin Dose (U/kg Body Weight) to Week 12 and Week 24
Units per kilogram (U/kg)ToujeoTresiba
Week 120.289 ± 0.2000.255 ± 0.195
Week 240.357 ± 0.2530.309 ± 0.241
SecondaryPercentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks (24W)). Percentage of participants with at least one hypoglycemia (hypo) event at any time of the day were reported.

Time frame:
Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) by Study Period
percentage of participantsToujeoTresiba
Any hypo Day1-Week 1253.058.4
Any hypo Week13-1457.257.4
Any hypo 24 week period70.171.2
Severe and/or confirmed hypo (=<70mg/dL) D1-W1247.454.3
Severe and/or confirmed hypo (=<70mg/dL) W13-1454.155.8
Severe and/or confirmed hypo(=<70mg/dL) 24W period66.569.0
Severe and/or confirmed hypo (< 54mg/dL) D1-W127.811.7
Severe and/or confirmed hypo( <54 mg/dL) W13-149.811.2
Severe and/or confirmed hypo (<54mg/dL) 24W period14.718.4
SecondaryPercentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycaemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time). Assessment was done by treatment period (for =\<12 weeks, for \>12 weeks to =\<24 weeks).

Time frame:
Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Reported as:
Number · percentage of participants
Percentage of Participants With At Least One Hypoglycemic Events (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal) by Study Period
percentage of participantsToujeoTresiba
Any hypo D1-W1218.421.0
Any hypo W13-1422.721.2
Any hypo 24Week period31.230.3
Severe and/or confirmed hypo (=<70mg/dL)D1-W1215.218.8
Severe and/or confirmed hypo (=<70mg/dL)W13-1421.421.0
Severe and/or confirmed hypo(=<70mg/dL)24W Period28.628.8
Severe and/or confirmed hypo(< 54mg/dL)D1-W122.83.5
Severe and/or confirmed hypo(< 54mg/dL)W13-144.53.8
Severe and/or confirmed hypo(< 54mg/dL)24W Period6.16.1
SecondaryHypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L).

Time frame:
Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Reported as:
Number · Events per participant year
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Any Time of the Day) Event Rate Per Participant Year During Study Period
Events per participant yearToujeoTresiba
Any hypo Day1-Week128.9311.31
Any hypo Week13-1411.2811.60
Any hypo 24 Week period10.0911.45
Severe and/or confirmed hypo (=<70mg/dL) D1-W128.0810.47
Severe and/or confirmed hypo (=<70mg/dL) W13-1410.6411.21
Severe and/or confirmed hypo (≤70mg/dL) 24W period9.3410.83
Severe and/or confirmed hypo (< 54mg/dL) D1-W120.490.86
Severe and/or confirmed hypo( <54 mg/dL) W13-140.730.91
Severe and/or confirmed hypo (<54mg/dL) 24W period0.610.88
Other pre-specifiedChange From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24

The DTSQs is a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consists of 8 items that are answered on a Likert scale from 0 to 6. Total treatment satisfaction score is the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment). Adjusted least square means and standard errors were obtained from a mixed-effect model with MMRM.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Least squares mean · score on a scale
Change From Baseline in Total Diabetes Treatment Satisfaction Questionnaire (DTSQ) Status at Week 12 and Week 24
score on a scaleToujeoTresiba
Week 125.08 ± 0.2465.32 ± 0.245
Week 245.77 ± 0.2575.44 ± 0.256
SecondaryHypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Severe and/or confirmed hypoglycemia event was a severe event or an event confirmed with plasma glucose =\<70 mg/dL (=\<3.9 mmol/L), or \< 54 mg/dL (\<3.0 mmol/L). Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time).

Time frame:
Day 1-Week 12, Week 13-Week 24, and 24 Week Period
Reported as:
Number · Events per participant year
Hypoglycemia (Any, Severe and/or Confirmed Hypoglycemia: Nocturnal ) Event Rate Per Participant Year During Study Period
Events per participant yearToujeoTresiba
Any hypo D1-W121.652.36
Any hypo W13-142.322.39
Any hypo 24Week period1.982.38
Severe and/or confirmed hypo(=<70mg/dL)D1-W121.422.20
Severe and/or confirmed hypo(=<70mg/dL)W13-142.242.33
Severe and/or confirmed hypo(=<70mg/dL)24W Period1.832.26
Severe and/or confirmed hypo(< 54mg/dL)D1-W120.160.19
Severe and/or confirmed hypo(< 54mg/dL)W13-140.330.26
Severe and/or confirmed hypo(< 54mg/dL)24W Period0.240.22

Adverse events

Collected over All Adverse Events were collected from signature of the informed consent form until 7 days after last treatment administration (maximum exposure: 24 Weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Toujeo1/462 (0.2%)21/462 (4.5%)56/462 (12.1%)
Tresiba0/462 (0%)20/462 (4.3%)58/462 (12.6%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventToujeoTresiba
Acute Myocardial InfarctionCardiac disorders0/4623/462
Ischaemic StrokeNervous system disorders0/4623/462
Non-Cardiac Chest PainGeneral disorders0/4622/462
CellulitisInfections and infestations1/4622/462
Atrial FlutterCardiac disorders0/4621/462
BradycardiaCardiac disorders1/4620/462
Cardiac ArrestCardiac disorders0/4621/462
Coronary Artery DiseaseCardiac disorders1/4621/462
Coronary Artery InsufficiencyCardiac disorders0/4621/462
Myocardial InfarctionCardiac disorders1/4620/462
Most frequent other events
Most frequent other events
EventToujeoTresiba
Viral Upper Respiratory Tract InfectionInfections and infestations38/46240/462
Upper Respiratory Tract InfectionInfections and infestations24/46219/462

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)ToujeoTresibaTotal
Mean60.6 ± 9.660.5 ± 9.860.5 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)ToujeoTresibaTotal
Female219211430
Male247252499
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ToujeoTresibaTotal
Count of participants——0
Body Mass Index (BMI)
Body Mass Index (BMI)(Kg/m^2)ToujeoTresibaTotal
Mean31.7 ± 4.331.3 ± 4.431.5 ± 4.4
Duration of Type 2 Diabetes Mellitus
Duration of Type 2 Diabetes Mellitus(years)ToujeoTresibaTotal
Mean10.5 ± 6.110.7 ± 6.510.6 ± 6.3
Baseline HbA1c
Baseline HbA1c(Percentage of HbA1c)ToujeoTresibaTotal
Mean8.71 ± 0.838.57 ± 0.808.64 ± 0.82
Basal Insulin Daily Dose
Basal Insulin Daily Dose(Units per kilogram (U/kg))ToujeoTresibaTotal
Mean0.19 ± 0.040.12 ± 0.030.15 ± 0.05
08

Study locations

158 sites
  • Investigational Site Number 840038
    Sheffield, Alabama 35660, United States
  • Investigational Site Number 840066
    Phoenix, Arizona 85020, United States
  • Investigational Site Number 840051
    Anaheim, California 92801, United States
  • Investigational Site Number 840081
    Chino, California 91710, United States
  • Investigational Site Number 840016
    Huntington Park, California 90255, United States
  • Investigational Site Number 840002
    La Jolla, California 92037, United States
  • Investigational Site Number 840091
    Los Angeles, California 90017, United States
  • Investigational Site Number 840058
    Northridge, California 91324, United States
  • Investigational Site Number 840021
    Palm Springs, California 92262, United States
  • Investigational Site Number 840087
    Santa Ana, California 92704, United States
  • Investigational Site Number 840030
    Torrance, California 90505, United States
  • Investigational Site Number 840065
    Van Nuys, California 91405, United States
  • Investigational Site Number 840075
    Bradenton, Florida 34201, United States
  • Investigational Site Number 840076
    New Port Richey, Florida 34652, United States
  • Investigational Site Number 840026
    Ocoee, Florida 34761, United States
  • Investigational Site Number 840052
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840080
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840018
    Port Charlotte, Florida 33952, United States
  • Investigational Site Number 840071
    Lawrenceville, Georgia 30046, United States
  • Investigational Site Number 840085
    Roswell, Georgia 30076, United States
  • Investigational Site Number 840072
    Statesboro, Georgia 30461, United States
  • Investigational Site Number 840039
    Stockbridge, Georgia 30281, United States
  • Investigational Site Number 840036
    Arlington Heights, Illinois 60005, United States
  • Investigational Site Number 840010
    Chicago, Illinois 60616, United States
  • Investigational Site Number 840005
    Avon, Indiana 46123, United States
  • Investigational Site Number 840063
    Council Bluffs, Iowa 51501, United States
  • Investigational Site Number 840098
    Des Moines, Iowa 50134, United States
  • Investigational Site Number 840101
    Des Moines, Iowa 50314, United States
  • Investigational Site Number 840096
    West Des Moines, Iowa 50266, United States
  • Investigational Site Number 840061
    Paris, Kentucky 40361, United States
  • Investigational Site Number 840011
    Hyattsville, Maryland 20782, United States
  • Investigational Site Number 840001
    Rockville, Maryland 20852, United States
  • Investigational Site Number 840041
    Flint, Michigan 48504, United States
  • Investigational Site Number 840057
    Flint, Michigan 48532, United States
  • Investigational Site Number 840033
    Troy, Michigan 48085, United States
  • Investigational Site Number 840084
    Olive Branch, Mississippi 38654, United States
  • Investigational Site Number 840048
    Chesterfield, Missouri 63017, United States
  • Investigational Site Number 840023
    Las Vegas, Nevada 89117, United States
  • Investigational Site Number 840045
    Las Vegas, Nevada 89128, United States
  • Investigational Site Number 840031
    Linden, New Jersey 07036, United States
  • Investigational Site Number 840060
    Hickory, North Carolina 28601, United States
  • Investigational Site Number 840064
    Morganton, North Carolina 28655, United States
  • Investigational Site Number 840043
    Wilmington, North Carolina 28401, United States
  • Investigational Site Number 840082
    Winston-Salem, North Carolina 27103, United States
  • Investigational Site Number 840025
    Oklahoma City, Oklahoma 73104, United States
  • Investigational Site Number 840022
    Oklahoma City, Oklahoma 73112, United States
  • Investigational Site Number 840029
    Beaver, Pennsylvania 15009, United States
  • Investigational Site Number 840056
    Downingtown, Pennsylvania 19335, United States
  • Investigational Site Number 840093
    Anderson, South Carolina 29621, United States
  • Investigational Site Number 840097
    Greenville, South Carolina 29605, United States
  • Investigational Site Number 840070
    Greer, South Carolina 29651, United States
  • Investigational Site Number 840044
    North Myrtle Beach, South Carolina 29582, United States
  • Investigational Site Number 840069
    Simpsonville, South Carolina 29681, United States
  • Investigational Site Number 840079
    Bristol, Tennessee, United States
  • Investigational Site Number 840006
    Chattanooga, Tennessee 37404, United States
  • Investigational Site Number 840088
    Knoxville, Tennessee 37912, United States
  • Investigational Site Number 840077
    New Tazewell, Tennessee 37825, United States
  • Investigational Site Number 840007
    Dallas, Texas 75230, United States
  • Investigational Site Number 840086
    Dallas, Texas 75231, United States
  • Investigational Site Number 840027
    Houston, Texas 77061, United States
  • Investigational Site Number 840004
    Houston, Texas 77083-4436, United States
  • Investigational Site Number 840040
    Houston, Texas 77090, United States
  • Investigational Site Number 840046
    Houston, Texas 77095, United States
  • Investigational Site Number 840054
    Hurst, Texas 76054, United States
  • Investigational Site Number 840017
    Mesquite, Texas 75149, United States
  • Investigational Site Number 840008
    Missouri City, Texas 77459, United States
  • Investigational Site Number 840094
    San Antonio, Texas 78229-3907, United States
  • Investigational Site Number 840009
    Sugar Land, Texas 77478, United States
  • Investigational Site Number 840053
    Waco, Texas 76710, United States
  • Investigational Site Number 840095
    Ogden, Utah 84405, United States
  • Investigational Site Number 840032
    Salt Lake City, Utah 84102, United States
  • Investigational Site Number 840024
    Norfolk, Virginia, United States
  • Investigational Site Number 840020
    Richmond, Virginia 23219, United States
  • Investigational Site Number 840012
    Renton, Washington 98055, United States
  • Investigational Site Number 100001
    Sofia, 1431, Bulgaria
  • Investigational Site Number 100002
    Sofia, 1505, Bulgaria
  • Investigational Site Number 100003
    Sofia, Bulgaria
  • Investigational Site Number 191001
    Rijeka, 51000, Croatia
  • Investigational Site Number 191002
    Rijeka, 51000, Croatia
  • Investigational Site Number 191003
    Zagreb, Croatia
  • Investigational Site Number 203009
    Hlucin, Czechia
  • Investigational Site Number 203006
    Jilove u Prahy, 25401, Czechia
  • Investigational Site Number 203005
    Liberec, 46001, Czechia
  • Investigational Site Number 203001
    Pardubice, 53002, Czechia
  • Investigational Site Number 203007
    Praha 1, 11000, Czechia
  • Investigational Site Number 203008
    Praha 2, 12808, Czechia
  • Investigational Site Number 203002
    Praha 8, 18100, Czechia
  • Investigational Site Number 203004
    Vsetin, 75501, Czechia
  • Investigational Site Number 208003
    Aarhus, 8000, Denmark
  • Investigational Site Number 208002
    Hillerød, 3400, Denmark
  • Investigational Site Number 208001
    København NV., 2400, Denmark
  • Investigational Site Number 208004
    Odense, 5000, Denmark
  • Investigational Site Number 250002
    La Roche Sur Yon, 85025, France
  • Investigational Site Number 250003
    La Rochelle Cedex 1, 17019, France
  • Investigational Site Number 250001
    Nantes cedex 01, 44093, France
  • Investigational Site Number 250006
    Nimes, 30029, France
  • Investigational Site Number 250005
    POITIERS Cedex, 86021, France
  • Investigational Site Number 250007
    Venissieux, 69200, France
  • Investigational Site Number 300005
    Alexandroupolis, 68100, Greece
  • Investigational Site Number 300001
    Athens, 17562, Greece

Showing the first 100 of 158 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, Sieber J, Stella P, Wang X, Frias JP, Roussel R, Bolli GB. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018 Oct;41(10):2147-2154. doi: 10.2337/dc18-0559. Epub 2018 Aug 13. PubMed 30104294 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 14, 2016
Start
May 19, 2016
Primary completionActual
Aug 15, 2017
CompletionActual
Aug 15, 2017
Results first posted
Sep 14, 2018
Last update
Sep 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02738151
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
May 19, 2016
Primary completion
Aug 15, 2017
Completion
Aug 15, 2017
Results posted
Sep 14, 2018
Last update
Sep 14, 2018

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion